Breakthrough Antibody Therapy Shows Promise Against Treatment-Resistant Breast Cancer
Key Insights
King's College London researchers developed a first-of-its-kind "triple-engineered antibody (search)" that simultaneously attacks tumor cells and activates immune defenses against aggressive breast cancers.
The modified antibody demonstrated superior immune cell activation compared to current treatments in laboratory experiments and animal models, particularly for triple-negative breast cancer (search) patients.
This innovative approach could address significant unmet medical needs for over 8,000 women diagnosed annually with triple-negative breast cancer (search) in the UK, where treatment options remain limited.
Scientists at King's College London have developed a groundbreaking antibody therapy that could transform treatment options for patients with the most aggressive forms of breast cancer (search). The innovative "triple-engineered antibody (search)" represents the first therapy of its kind to simultaneously attack tumor cells directly while harnessing the body's immune system to fight cancer.
The research, published in Cancer Research, addresses a critical gap in treating triple-negative breast cancer (search) (TNBC) and treatment-resistant cancers, where current therapeutic options remain severely limited. Triple-negative breast cancer accounts for approximately 15% of all breast cancers and lacks receptors for estrogen, progesterone, and HER2 (search) protein that serve as common drug targets in other breast cancer (search) subtypes.
Novel Dual-Action Mechanism
The breakthrough antibody employs a unique dual-targeting approach, latching onto cancer cells on one end while drawing in immune cells on the other. Laboratory experiments and animal models demonstrated that this modified antibody bound immune cells more strongly compared to current treatments, effectively activating immune cells already present within tumors to attack cancer cells.
"By making a few key changes in the structure of the antibody, we found that it could activate the immune system much more powerfully than an unmodified antibody currently used in breast cancer (search) treatment," explained Dr. Alicia Chenoweth, first author from King's College London's Faculty of Life Sciences & Medicine.
The research revealed that many immune cells within breast tumors exist in a "suppressed" state, making them difficult to activate with conventional unmodified antibodies. The triple-engineered antibodies not only activated these immune cells to eliminate cancer cells but also shifted them to a more activated state overall.
Addressing Treatment-Resistant Cancers
The therapy specifically targets patients whose cancers no longer respond to existing treatments, representing a significant advancement for those facing limited therapeutic options. Professor Sophia Karagiannis, lead author and expert in Translational Cancer Immunology at King's College London, emphasized the therapy's potential impact.
"By examining key immune cell receptors in breast tumors, including those tumors resistant to chemotherapy and immunotherapy, we have designed our antibody to make them interact better and harness the immune system in a way that has never been done or tested in cancer before," Karagiannis stated.
The research demonstrated that the modified antibody also activated immune cells circulating in the bloodstream, potentially boosting the body's overall ability to detect and fight cancer throughout the system.
Clinical Significance for High-Risk Populations
Triple-negative breast cancer (search) disproportionately affects younger women and Black women, with over 8,000 women diagnosed annually in the UK alone. This subtype presents particular challenges as standard hormone therapies and HER2 (search)-targeting drugs prove ineffective, leaving patients with fewer treatment options and higher recurrence risks.
Dr. Simon Vincent, chief scientific officer at Breast Cancer (search) Now, highlighted the urgent need addressed by this research: "This promising, early-stage research offers hope for more and better treatments for over 8,000 women who are diagnosed with triple negative breast cancer each year in the UK. We know how urgently these women need new treatment options, as this form of the disease can be more challenging to treat, may be more likely to return or spread in the first few years following treatment."
Broader Cancer Applications
The therapeutic approach extends beyond breast cancer (search) applications. Researchers identified that one of the antibody targets is also present in ovarian and endometrial cancers, suggesting potential clinical applications for these diseases as well.
The King's College London team continues advancing this research toward clinical application, working to optimize the therapy by extending antibody longevity in the body and ensuring activation of broader immune cell types. The Breast Cancer Now Research Unit (search) at King's College London has been at the forefront of antibody modification research for over a decade, focusing on innovative approaches to activate patient immune responses.
This development represents a significant step forward in addressing treatment-resistant breast cancers, offering new hope for patients facing the most challenging forms of the disease while potentially opening new therapeutic avenues across multiple cancer types.